CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Modifiable lifestyle factors and heart failure: A Mendelian randomization study Nuclear Imaging of the Cardiac Sympathetic Nervous System: A Disease-Specific Interpretation in Heart Failure A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF) Impact of Myocardial Scar on Prognostic Implication of Secondary Mitral Regurgitation in Heart Failure Sex Differences in Cardiovascular Pathophysiology: Why Women Are Overrepresented in Heart Failure With Preserved Ejection Fraction Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry Heart Failure and Atrial Fibrillation, Like Fire and Fury Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart Failure Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure Prdm16 Deficiency Leads to Age-Dependent Cardiac Hypertrophy, Adverse Remodeling, Mitochondrial Dysfunction, and Heart Failure

Editorial17 Nov 201

JOURNAL:Circulation. Article Link

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF

Martinez FA, Serenelli M, Nicolau JC et al. Keywords: dapagliflozin; HFrEF; efficacy; safety

FULL TEXT PDF